Nyrada Inc. (NYR.AX)
AUD 0.11
(0.0%)
AUD 0.11
(0.0%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 | -4.56 Million AUD | 50.16% |
| 2023 | -9.15 Million AUD | -88.2% |
| 2022 | -4.86 Million AUD | 13.23% |
| 2021 | -5.6 Million AUD | 14.31% |
| 2020 | -6.53 Million AUD | -67.57% |
| 2019 | -3.9 Million AUD | -81.16% |
| 2018 | -2.15 Million AUD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q4 | -2.25 Million AUD | 0.0% |
| 2024 FY | -4.56 Million AUD | 50.16% |
| 2024 Q2 | -2.3 Million AUD | 0.0% |
| 2023 FY | -9.15 Million AUD | -88.2% |
| 2023 Q2 | -3.73 Million AUD | 0.0% |
| 2023 Q4 | -5.41 Million AUD | 0.0% |
| 2022 Q4 | -2.04 Million AUD | 0.0% |
| 2022 FY | -4.86 Million AUD | 13.23% |
| 2022 Q2 | -2.81 Million AUD | 0.0% |
| 2021 Q4 | -2.9 Million AUD | 0.0% |
| 2021 FY | -5.6 Million AUD | 14.31% |
| 2021 Q2 | -2.74 Million AUD | 0.0% |
| 2020 FY | -6.53 Million AUD | -67.57% |
| 2020 Q4 | -4.2 Million AUD | 0.0% |
| 2020 Q2 | -2.24 Million AUD | 0.0% |
| 2019 Q2 | -2.27 Million AUD | -100.0% |
| 2019 Q4 | -1.19 Million AUD | 0.0% |
| 2019 FY | -3.9 Million AUD | -81.16% |
| 2019 Q1 | -1.13 Million AUD | 0.0% |
| 2018 FY | -2.15 Million AUD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| AdAlta Limited | -5.26 Million AUD | 13.328% |
| Acrux Limited | -9.83 Million AUD | 53.627% |
| Actinogen Medical Limited | -12.83 Million AUD | 64.481% |
| AnteoTech Limited | -11.72 Million AUD | 61.111% |
| Argenica Therapeutics Limited | -5.67 Million AUD | 19.588% |
| Arovella Therapeutics Limited | -7.19 Million AUD | 36.601% |
| Anatara Lifesciences Ltd | -1.45 Million AUD | -212.538% |
| Alterity Therapeutics Limited | -19.6 Million AUD | 76.735% |
| Amplia Therapeutics Limited | -4.42 Million AUD | -3.059% |
| Avecho Biotechnology Limited | -4.58 Million AUD | 0.629% |
| Bio-Gene Technology Limited | -3.06 Million AUD | -48.911% |
| Biome Australia Limited | -1.91 Million AUD | -138.356% |
| Biotron Limited | -5.15 Million AUD | 11.47% |
| Botanix Pharmaceuticals Limited | -14.69 Million AUD | 68.977% |
| BTC Health Limited | 1.05 Million AUD | 532.141% |
| Chimeric Therapeutics Limited | -12.3 Million AUD | 62.953% |
| CSL Limited | 5.64 Billion AUD | 100.081% |
| Clarity Pharmaceuticals Ltd | -44.8 Million AUD | 89.821% |
| Clinuvel Pharmaceuticals Limited | 49.14 Million AUD | 109.279% |
| Cynata Therapeutics Limited | -8.8 Million AUD | 48.225% |
| Dimerix Limited | -25.05 Million AUD | 81.802% |
| EZZ Life Science Holdings Limited | 9.71 Million AUD | 146.934% |
| Hexima Limited | -1 Million AUD | -352.077% |
| Island Pharmaceuticals Limited | -2.87 Million AUD | -58.687% |
| Immuron Limited | -5.8 Million AUD | 21.389% |
| Immutep Limited | -44.93 Million AUD | 89.852% |
| Imugene Limited | -140.93 Million AUD | 96.764% |
| Invex Therapeutics Ltd | -2.13 Million AUD | -113.736% |
| Memphasys Limited | -2.7 Million AUD | -68.651% |
| Nanollose Limited | -1.24 Million AUD | -264.877% |
| Neuren Pharmaceuticals Limited | 225.96 Million AUD | 102.018% |
| Noxopharm Limited | -7.53 Million AUD | 39.478% |
| NeuroScientific Biopharmaceuticals Limited | -2.05 Million AUD | -121.746% |
| Orthocell Limited | -11.68 Million AUD | 60.96% |
| PharmAust Limited | -6.65 Million AUD | 31.512% |
| Patrys Limited | -3.53 Million AUD | -28.854% |
| Paradigm Biopharmaceuticals Limited | -65.11 Million AUD | 92.996% |
| Proteomics International Laboratories Limited | -7.23 Million AUD | 36.938% |
| Prescient Therapeutics Limited | -7.18 Million AUD | 36.542% |
| PYC Therapeutics Limited | -38.85 Million AUD | 88.264% |
| Race Oncology Limited | -13.38 Million AUD | 65.918% |
| Radiopharm Theranostics Limited | -47.2 Million AUD | 90.34% |
| Recce Pharmaceuticals Ltd | -22.05 Million AUD | 79.319% |
| Starpharma Holdings Limited | -15.15 Million AUD | 69.917% |
| Telix Pharmaceuticals Limited | - AUD | Infinity% |
| Tissue Repair Ltd | -4.87 Million AUD | 6.473% |
| Zelira Therapeutics Limited | -5.93 Million AUD | 23.204% |